- Home
- CRON vs QURE Comparison
CRON vs QURE Comparison
Compare CRON & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | Netherlands |
| Employees | N/A | 248 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 1.1B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CRON | QURE |
|---|---|---|
| Price | $2.73 | $24.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $146,587,000.00 | $13,107,000.00 |
| Revenue This Year | $26.34 | $126.12 |
| Revenue Next Year | $15.53 | $200.43 |
| P/E Ratio | $68.38 | ★ N/A |
| Revenue Growth | ★ 24.63 | N/A |
| 52 Week Low | $1.84 | $8.73 |
| 52 Week High | $3.43 | $71.50 |
Technical Indicators
Market Signals| Indicator | CRON | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 57.91 |
| Support Level | $2.47 | $21.16 |
| Resistance Level | $2.72 | $25.66 |
| Average True Range (ATR) | 0.10 | 2.18 |
| MACD | 0.00 | -0.29 |
| Stochastic Oscillator | 39.23 | 48.23 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.